INCYNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

INCYTE CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026

$113.25+0.18 (+0.16%)

Close on Oct 19, 2026

Market cap: $23.58B
P/E (TTM): 14.4
Dividend yield: –

INCYTE CORP income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	5,141	4,241	3,696	3,395	2,986	2,667	2,159	1,882	1,536	1,106	754	511	355	297	94	170	9.27
Cost of Revenue	372	312	255	207	151	131	114	94	79	58	27	3.00	0.63	0.16	–	–	–
Gross Profit	4,769	3,929	3,441	3,188	2,835	2,535	2,045	1,788	1,457	1,048	727	508	354	297	–	–	–
Research & Development	2,050	2,607	1,628	1,586	1,458	2,216	1,154	1,198	1,326	582	480	348	260	210	179	124	119
Selling, General & Admin	1,376	1,242	1,156	1,002	740	517	469	434	366	303	197	166	110	85	58	32	28
Advertising Expenses	156	201	222	196	66	29	15	11	–	–	–	–	–	–	–	–	–
Total Costs & Expenses	3,626	4,180	3,075	2,815	2,400	2,930	1,757	1,753	1,780	961	703	516	371	296	238	156	149
Operating Income	1,515	61	621	579	586	-264	402	129	-243	145	51	-4.80	-16	1.15	-143	14	-140
Interest Expense	2.43	2.28	2.55	2.67	1.91	2.17	1.86	1.54	6.90	39	46	47	39	46	44	43	32
Interest & Investment Income	106	129	158	40	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	25	13	14	-0.52	11	23	52	32	17	–	–	–	–	–	–	–	–
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.09	-0.38	2.01
Asset Impairment Charges	76	0	5.63	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	21	116	44	-88	–	–	–	–	–	-0.20	1.80	0	0	0.55	-0.19	0.18	-0.09
Legal Settlements	242	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	1,664	317	834	529	570	-232	487	115	-312	107	7.56	-49	-83	-44	-187	-32	–
Income Tax Expense	378	284	237	188	-378	63	40	5.85	0.85	3.18	1.03	-0.07	0.30	0.17	–	–	–
Net Income incl. Noncontrolling Interests	1,287	33	598	341	949	-296	447	109	-313	104	–	–	–	–	–	–	–
Net Income	1,287	33	598	341	949	-296	447	109	-313	104	–	–	–	–	–	–	–
Net Income to Common	1,287	33	598	341	949	-296	447	109	-313	104	6.53	-48	-83	-44	-187	-32	-212
EPS (Basic)(per share)	6.59	0.16	2.67	1.53	4.30	-1.36	2.08	0.52	-1.53	0.55	0.04	-0.29	-0.56	-0.34	-1.49	-0.26	-2.06
EPS (Diluted)(per share)	6.41	0.15	2.65	1.52	4.27	-1.36	2.05	0.51	-1.53	0.54	0.03	-0.29	-0.56	-0.34	-1.49	-0.26	-2.06
Shares Outstanding (Basic, Weighted)(shares)	195	207	224	222	220	218	215	212	205	188	180	168	148	130	125	122	103
Shares Outstanding (Diluted, Weighted)(shares)	201	211	226	224	222	218	218	216	205	194	187	168	148	130	125	122	103
EBITDA	1,608	151	703	647	644	-212	457	184	-191	203	96	37	13	31	-116	39	-123

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 92.6%
Operating margin: 30.6%
Net margin: 27.7%
Return on equity, FY2025: 29.9%

Financial strength

Current ratio: 4.59
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 303.5%

Valuation

P/E ratio: 14.4
Price to sales: 4.05
Price to book: 3.72
Dividend yield: –